


REMARKS

Claims 1-15 remain herein. Claims 1-15 have been amended. Support for the amendments may be found throughout the specification (see, e.g., compound (H3) at page 26 of the specification).


Applicants' thank the Examiner for the telephonic interview conducted on February 25, 2008. During the interview agreement was reached that Inoue et al. U.S. Patent 6,344,283 does not teach the claimed aromatic diamine derivative represented by following general formula (1):



wherein A represents a diarylamino group represented by:



B represents a diarylamino group represented by:



Ar¹ to Ar⁴ each independently representing a substituted or unsubstituted aryl group having 5 to 50 nuclear atoms, with the proviso that Ar¹ to Ar⁴ are not substituted with an amino group. The Examiner agreed that such a limitation would potentially distinguish applicants' claim from Inoue. The arguments made during the interview are included in the remarks below herein.


Serial No. 10/542,105
Atty Dkt No. 28955.4030

1. Claims 1-6 and 8-15 were rejected under 35 U.S.C. § 102(e) over Inoue et al. U.S. Patent 6,344,283.


Claims 1 and 8 recite an aromatic diamine derivative represented by general formula (1):



wherein A represents a diarylamino group represented by:



B represents a diarylamino group represented by:




and Ar¹ to Ar⁴ each independently represents a substituted or unsubstituted aryl group having 5 to 50 nuclear atoms, with the proviso that Ar¹ to Ar⁴ are not substituted with an amino group.


Because applicants' claimed formula (1) recites an aromatic diamine derivative and Ar¹ to Ar⁴ are not substituted with an amino group, formula (1) can have only two nitrogen atoms in the main skeleton.

Inoue does not disclose applicants' claimed formula (1). Inoue discloses the following formula V:

(V)



Contrary to the Examiner's assertion in the Advisory Action of January 18, 2008, R₀₁ to R₀₄ cannot be phenyl because they are one of the following groups:




See, e.g., Inoue at Abstract; column 5, line 66 to column 6, line 20; and claim 1. Thus, unlike applicants' claimed formula (1), in Inoue formula (V), the phenyl groups are substituted with R₀₁ to R₀₄ which include an amino group.


Thus, Inoue does not disclose all elements of applicants' claims and, therefore, it is not an adequate basis for a rejection under § 102(e). Applicants respectfully request reconsideration and withdrawal of this rejection.

2. Claim 7 was rejected under 35 U.S.C. § 102(b) over Nakaya et al. U.S. Patent 5,792,557. The Office Action states that applicants' claimed compound (H10) reads on Nakaya's formula (1) when r1 to r4 are 1, r5 and r6 are 0, R₁ and R₃ are phenyl, and R₂ and R₄ are naphthyl.

Applicants' compound (H10) has the following structural formula:



Nakaya does not disclose compound (H10). Nakaya's formula (1) is the following:



Serial No. 10/542,105
Atty Dkt No. 28955.4030

When Nakaya's R₂ and R₄ groups are naphthyl groups, the resulting groups linked to the nitrogen atom are not naphthyl groups as in applicants' claimed compound (H10) but phenyl groups substituted with naphthyl groups.

Thus, Nakaya does not disclose all elements of applicants' claims and, therefore, it is not an adequate basis for a rejection under § 102(b). Applicants respectfully request reconsideration and withdrawal of this rejection.

For all of the foregoing reasons, all claims 1-15 are now fully in condition for allowance, which is respectfully requested. The PTO is hereby authorized to charge or credit any necessary fees to Deposit Account No. 19-4293. Should the Examiner deem that any further amendments would be desirable in placing this application in even better condition for issue, she is invited to telephone applicant's undersigned representative.

Respectfully submitted,

Date: March 28,2008

Houda MORAD
Roger W. Parkhurst
Reg. No. 25,177
Houda Morad
Registration No. 56,742

STEPTOE & JOHNSON LLP
1330 Connecticut Ave., N.W.
Washington, D.C. 20036
Tel: (202) 429-3000
Fax: (202) 429-3902